share_log

We Think That There Are More Issues For Sichuan Hezong Medicine Easy-to-buy Pharmaceutical (SZSE:300937) Than Just Sluggish Earnings

We Think That There Are More Issues For Sichuan Hezong Medicine Easy-to-buy Pharmaceutical (SZSE:300937) Than Just Sluggish Earnings

我们认为,四川合众药易购药业(深交所股票代码:300937)面临的问题不仅仅是收益疲软
Simply Wall St ·  05/01 18:38

The subdued market reaction suggests that Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd.'s (SZSE:300937) recent earnings didn't contain any surprises. Our analysis suggests that along with soft profit numbers, investors should be aware of some other underlying weaknesses in the numbers.

疲软的市场反应表明,四川合宗医药易购药业有限公司s(深圳证券交易所代码:300937)最近的收益没有任何意外。我们的分析表明,除了疲软的利润数字外,投资者还应意识到这些数字中的其他一些潜在弱点。

earnings-and-revenue-history
SZSE:300937 Earnings and Revenue History May 1st 2024
SZSE: 300937 2024 年 5 月 1 日的收益和收入历史记录

How Do Unusual Items Influence Profit?

不寻常的物品如何影响利润?

For anyone who wants to understand Sichuan Hezong Medicine Easy-to-buy Pharmaceutical's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥7.9m worth of unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And that's as you'd expect, given these boosts are described as 'unusual'. If Sichuan Hezong Medicine Easy-to-buy Pharmaceutical doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

对于任何想了解四川合众药易购药业在法定数字之外的利润的人来说,值得注意的是,在过去的十二个月中,从价值790万元人民币的不寻常物品中获得了法定利润。虽然我们希望看到利润增加,但当不寻常的物品做出重大贡献时,我们往往会更加谨慎一些。我们统计了全球大多数上市公司的数字,不寻常的物品在自然界中很常见。这正如你所预料的那样,因为这些增强被描述为 “不寻常”。如果四川合宗药业易购药业没有看到这种捐款重演,那么在其他条件相同的情况下,我们预计其利润将在本年度下降。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical.

注意:我们始终建议投资者检查资产负债表的实力。点击此处查看我们对四川合宗医药易购药业的资产负债表分析。

Our Take On Sichuan Hezong Medicine Easy-to-buy Pharmaceutical's Profit Performance

我们对四川合众药易购药业盈利表现的看法

Arguably, Sichuan Hezong Medicine Easy-to-buy Pharmaceutical's statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Sichuan Hezong Medicine Easy-to-buy Pharmaceutical's statutory profits are better than its underlying earnings power. Sadly, its EPS was down over the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. While conducting our analysis, we found that Sichuan Hezong Medicine Easy-to-buy Pharmaceutical has 3 warning signs and it would be unwise to ignore these.

可以说,四川合宗药业易购药业的法定收益被提高利润的不寻常项目所扭曲。正因为如此,我们认为四川合众药易购药业的法定利润可能好于其基础盈利能力。不幸的是,在过去的十二个月中,其每股收益有所下降。本文的目标是评估我们在多大程度上可以依靠法定收益来反映公司的潜力,但还有很多需要考虑的地方。请记住,在分析股票时,值得注意所涉及的风险。在进行分析时,我们发现四川合众药易购药业有三个警告信号,忽视这些信号是不明智的。

Today we've zoomed in on a single data point to better understand the nature of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

今天,我们放大了单一数据点,以更好地了解四川合众药易购药业利润的性质。但是,还有很多其他方法可以让你对公司的看法。有些人认为高股本回报率是优质业务的好兆头。因此,你可能希望看到这份免费收藏的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发